December 24, 2004Cardiovascular Research
The effects of PPAR-? ligand pioglitazone on platelet aggregation and arterial thrombus formation
Why the study?
Does pioglitazone reduce platelet aggregation and arterial thrombus formation in Sprague-Dawley rats?
Population
Sprague-Dawley rats
Comparison
Pioglitazone mixed in chow for 7 to 10 days vs Control
Design
Preclinical
Follow-up
7 to 10 days
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for pioglitazone antithrombotic effects in rats; human trials needed before clinical consideration.
Structured PICO
Does pioglitazone reduce platelet aggregation and arterial thrombus formation in Sprague-Dawley rats?
P
Population
Sprague-Dawley rats
I
Intervention
Pioglitazone (1 or 10 mg/kg/day) mixed in chow for 7 to 10 days
C
Comparator
Control
O
Outcome
Time to occlusive thrombus formationsurrogate
In a rat model, pioglitazone decreased platelet aggregation and delayed intra-arterial thrombus formation, suggesting potential anti-thrombotic effects.
Cite This Study
Li et al. (2004) studied this question.